Although these previous reports suggest that both adiponectin and PFAAs could be useful for the early detection of future T2DM risk, the potential of PFAAs as biomarkers has not been fully elucidated compared with that of the serum adiponectin level, which has been widely regarded as a surrogate marker for metabolic status in the body. The gene discussed is ADIPOQ; the disease is type 2 diabetes mellitus.